Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-6723 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT07749586Phase 2Recruiting
- Sponsor
- Arvinas
- Start
- Jul 2026
- Primary completion
- Mar 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial of ARV-6723 in solid tumor (advanced stage) (7 arms), sponsored by Arvinas. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events up to 4.7 years and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
ARV-6723
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07749586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749586.